The PERCEPTION study aims to assess the correlation between blood cell counts (Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio) and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating Lymphocytes (TILs), at baseline and after surgery, for patients diagnosed with triple negative breast cancer. It also aims to assess these circulating elements and circulating tumor DNA as predictive factor of metastatic recurrence in triple negative breast cancer.
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer. Because of the limited therapeutical strategies, early TNBC relapses are quite common during the five years following treatment. It has been shown that the presence of tumor infiltrating lymphocytes (TILs) at baseline is related to good pathological response to neoadjuvant chemotherapy. In addition, the presence of a high quantity of TILs in the residual tumor after neoadjuvant chemotherapy is related to better survival rates. Blood circulating elements, such as peripheral blood cells or circulating tumor DNA, could be of interest in predicting response to treatment and in the prediction of metastatic recurrences in different types of cancer, including breast cancer. However, the correlation of these markers in triple negative breast cancer has not yet been thoroughly studied. The PERCEPTION study aims to assess the correlation between blood cell counts (Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio) and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating Lymphocytes (TILs), at baseline and after surgery, for patients diagnosed with triple negative breast cancer. It also aims to assess these circulating elements and circulating tumor DNA as predictive factor of metastatic recurrence in triple negative breast cancer.
Study Type
OBSERVATIONAL
Enrollment
90
Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
Centre Jean PERRIN
Clermont-Ferrand, Please Select, France
RECRUITINGAssessment of the correlation between the lymphocyte infiltration rate assessed on biopsy, and the NLR (neutrophil-to-lymphocyte ratio) measured on blood samples, in women with triple negative breast cancer, at the time of diagnosis.
* The value of NLR at diagnosis; * Tumor lymphocyte infiltration rate before treatment.
Time frame: 3 years (the period of recruitment)
Assessment of the correlation between the TILs assessed on biopsy, and the various parameters derived from the blood count (leucocytes, neutrophils, lymphocytes, platelets and PLR (Platelet-to-Lymphocyte Ratio)), at the time of diagnosis.
* The values of leucocytes, lymphocytes, neutrophils, platelets and PLR at diagnosis; * Tumor lymphocyte infiltration rate before treatment
Time frame: 3 years (the period of recruitment)
Assessment of the correlation between the various parameters derived from the blood count (leucocytes, neutrophils, lymphocytes, platelets, NLR and PLR) at the time of diagnosis, and the histological response to neo-adjuvant chemotherapy
* The values of leucocytes, lymphocytes, neutrophils, platelets, NLR and PLR at diagnosis; * Histological response according to the Sataloff classification
Time frame: 3 years (the period of recruitment)
Assessment of the correlation between the various parameters derived from the blood count (leucocytes, neutrophils, lymphocytes, platelets, NLR and PLR) at the time of diagnosis, and the TILs at surgery specimen after neoadjuvant chemotherapy.
* The values of leucocytes, lymphocytes, neutrophils, platelets, NLR and PLR at diagnosis; * Tumor lymphocyte infiltration rate at surgery specimen
Time frame: 3 years (the period of recruitment)
Assessment of the correlation between the various parameters derived from the blood count (leucocytes, neutrophils, lymphocytes, platelets, NLR and PLR) before surgery, and the lymphocyte infiltration rate at surgery after neoadjuvant chemotherapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
* The values of leucocytes, lymphocytes, neutrophils, platelets, NLR and PLR before surgery; * Tumor lymphocyte infiltration rate at surgery specimen
Time frame: 3 years
Relationship between ctDNA and the metastatic relapse
* Measurement of plasma cDNA level * Metastatic relapse
Time frame: 8 years
Relationship between leucocyte value and the presence of circulating tumor DNA (ctDNA)
* The value of leucocytes * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between lymphocyte value and the presence of circulating tumor DNA (ctDNA)
* The value of lymphocytes * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between neutrophils value and the presence of circulating tumor DNA (ctDNA)
* The value of neutrophils * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between platelet value and the presence of circulating tumor DNA (ctDNA)
* The value of platelets * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between NLR value and the presence of circulating tumor DNA (ctDNA)
* The value of NLR * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between PLR value and the presence of circulating tumor DNA (ctDNA)
* The value of PLR * Measurement of plasma cDNA level
Time frame: 8 years
Relationship between all the blood parameters and the metastatic relapse
* The values of leucocytes, lymphocytes, neutrophils, platelets, NLR and PLR * Metastatic relapse
Time frame: 8 years